Another rheuma drug steps up in the battle against COVID-19
12 May 2020
byAudrey Abella
Use of the interleukin(IL)-1 inhibitor anakinra led to clinical improvements in patients with coronavirus disease (COVID)-19, acute respiratory distress syndrome (ARDS), and systemic inflammation who are under noninvasive ventilation outside the intensive care unit (ICU), an Italian retrospective study has shown.
